2seventy bio (TSVT) Revenue & Revenue Breakdown
2seventy bio Revenue Highlights
Latest Revenue (Y)
$37.86M
Latest Revenue (Q)
$2.93M
Main Segment (Y)
Collaboration Arrangement
2seventy bio Revenue by Period
2seventy bio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $37.86M | -62.28% |
| 2023-12-31 | $100.39M | 9.72% |
| 2022-12-31 | $91.50M | 67.81% |
| 2021-12-31 | $54.52M | -78.03% |
| 2020-12-31 | $248.12M | 460.15% |
| 2019-12-31 | $44.30M | -18.84% |
| 2018-12-31 | $54.58M | - |
2seventy bio generated $37.86M in revenue during NA 2024, up -62.28% compared to the previous quarter, and up 85.47% compared to the same period a year ago.
2seventy bio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $2.93M | -78.38% |
| 2024-09-30 | $13.53M | 50.93% |
| 2024-06-30 | $8.97M | -27.89% |
| 2024-03-31 | $12.44M | 16.39% |
| 2023-12-31 | $10.68M | -11.22% |
| 2023-09-30 | $12.03M | -66.62% |
| 2023-06-30 | $36.05M | -13.39% |
| 2023-03-31 | $41.62M | -25.91% |
| 2022-12-31 | $56.18M | 318.98% |
| 2022-09-30 | $13.41M | -0.55% |
| 2022-06-30 | $13.48M | 59.95% |
| 2022-03-31 | $8.43M | -47.43% |
| 2021-12-31 | $16.03M | -16.74% |
| 2021-09-30 | $19.26M | 162.79% |
| 2021-06-30 | $7.33M | -38.43% |
| 2021-03-31 | $11.90M | 20.15% |
| 2020-12-31 | $9.90M | -46.27% |
| 2020-09-30 | $18.43M | -83.23% |
| 2020-06-30 | $109.89M | - |
| 2020-03-31 | $109.89M | - |
2seventy bio generated $2.93M in revenue during Q4 2024, up -78.38% compared to the previous quarter, and up 24.31% compared to the same period a year ago.
2seventy bio Revenue Breakdown
2seventy bio Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|
| Collaboration Arrangement | $4.70M | $19.58M | - | - |
| Royalty And Other Revenue | - | $4.64M | $6.22M | - |
| Service | - | $24.14M | $55.49M | $21.38M |
Latest
2seventy bio's latest annual revenue breakdown by segment (product or service), as of Dec 24: Collaboration Arrangement (100.00%).
Quarterly Revenue by Product
| Product/Service | Mar 25 | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty And Other Revenue | $21.00K | - | $1.23M | $1.99M | $1.42M | $1.12M | $863.00K | $781.00K | $887.00K | $803.00K | $608.00K | - | - |
| Service | $3.77M | $7.72M | $8.30M | $5.02M | $10.83M | $41.13M | $4.64M | $5.67M | $4.05M | $3.84M | $6.31M | - | - |
| Collaboration Arrangement | - | - | $4.70M | - | - | - | - | - | - | - | - | - | - |
Latest
2seventy bio's latest quarterly revenue breakdown by segment (product or service), as of Mar 25: Service (99.45%), and Royalty And Other Revenue (0.55%).
2seventy bio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| SRPT | Sarepta Therapeutics | $1.90B | $658.41M |
| ASND | Ascendis Pharma | $266.72M | $95.89M |
| RCUS | Arcus Biosciences | $258.00M | $26.00M |
| PBYI | Puma Bio | $230.47M | $59.08M |
| IOVA | Iovance Biotherapeutics | $164.07M | $73.69M |
| DAWN | Day One Biopharmaceuticals | $131.16M | $29.21M |
| ZNTL | Zentalis Pharmaceuticals | $67.42M | $26.86M |
| PHAT | Phathom Pharmaceuticals | $55.25M | $28.52M |
| MRSN | Mersana Therapeutics | $40.50M | $12.60M |
| TSVT | 2seventy bio | $37.86M | $2.93M |
| STOK | Stoke Therapeutics | $36.55M | $22.61M |
| SNDX | Syndax Pharmaceuticals | $23.68M | $20.04M |
| RLAY | Relay Therapeutics | $10.01M | $7.68M |
| CRNX | Crinetics Pharmaceuticals | $1.04M | - |
| CGEM | Cullinan Oncology | - | - |
| PTGX | Protagonist Therapeutics | - | $170.64M |
| REPL | Replimune Group | - | - |
| KZR | Kezar Life Sciences | - | - |
| INZY | Inozyme Pharma | - | - |
| PLRX | Pliant Therapeutics | - | - |